Aclarubicin or aclacinomycin A is used to treat acute non lymphocytic leukemia, a cancer of the blood and bone marrow. It is an oligosaccharide anthracycline agent produced by a soil bacterium called Streptomyces galilaeus and has powerful anticancer activity.
Contraindicated in patients with severe heart disease, bone marrow depression, and hypersensitivity.
Adult: IV- Initial: 175-300 mg/m2, divided over 3-7 consecutive days. Maintenance: 25-100 mg/m2 3-4 weekly.
It comes as a solution for injection to be administered by a healthcare provider into the vein.
• Caution should be exercised in patients with history of liver or kidney impairment, radiation-induced heart attack, and use of radiotherapy, during pregnancy and breastfeeding.
• Monitor complete blood counts, liver function, uric acid level in blood regularly while taking this medication.
• Severe Effects :
Heart damage and bone marrow suppression.
• Gastrointestinal : Nausea, vomiting, irritant to tissue, sore mouth, diarrhea, and gastrointestinal tract inflammation.
• Blood : Anemia, bone-marrow suppression.
• Skin : Hair loss.
• Liver: Hepatic dysfunction.
• Genitourinary : Blood in urine.
Avoid live vaccination during the treatment period.
Avoid excess dosage.
IV Inj: Store at room temperature (20 to 25°C). Protect from sunlight. IV Inj (reconstituted solution): Store below 40°C. Use within 24 hours if kept at room temperature.
Subscribe to our Free Newsletters!